MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.95
+0.88
+4.18%
Closed 16:12 09/24 EDT
OPEN
20.86
PREV CLOSE
21.07
HIGH
22.59
LOW
20.49
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
29.20
52 WEEK LOW
7.73
MARKET CAP
1.55B
P/E (TTM)
-9.2565
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cytokinetics To Report New Data At Heart Failure Society Of America Meeting Sept. 30-Oct. 6
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020
Benzinga · 13h ago
Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020 – October 6, 2020
GlobeNewswire · 13h ago
Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular DiseasesDeadline for Applications is November 13th, 2020SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for
GlobeNewswire · 21h ago
Cytokinetics initiates early-stage study with its second myosin inhibitor in cardiovascular disorder
Cytokinetics (CYTK) has dosed the first participants in a Phase 1 single ascending dose clinical study of CK-3772271 (CK-271), a cardiac myosin inhibitor for the potential treatment of hypertrophic cardiomyopathy ((HCM)),
Seekingalpha · 1d ago
Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart
GlobeNewswire · 09/17 12:30
Cytokinetics Incorporated (CYTK) Investor Presentation - Slideshow
The following slide deck was published by Cytokinetics, Incorporated in conjunction with this event.
Seekingalpha · 09/14 17:48
Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the company will participate in four upcoming investor conferences. On September 9-10, 2020 Cytokinetics’ senior management team will participate in one-on-one meetings during
GlobeNewswire · 09/02 20:00
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
GlobeNewswire · 08/26 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTK. Analyze the recent business situations of Cytokinetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTK stock price target is 40.25 with a high estimate of 59.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 59.53M
% Owned: 84.43%
Shares Outstanding: 70.50M
TypeInstitutionsShares
Increased
61
5.31M
New
45
532.32K
Decreased
49
3.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Leonard Patrick Gage
Chief Executive Officer/President/Director
Robert Blum
Chief Financial Officer/Senior Vice President
Ching Jaw
Chief Human Resource Officer/Chief Administrative Officer
David Cragg
Executive Vice President
Fady Malik
Senior Vice President/General Counsel/Secretary
Mark Schlossberg
Chief Accounting Officer/Vice President
Robert Wong
Independent Director
Robert Califf
Independent Director
Santo Costa
Independent Director
John Henderson
Independent Director
Edward Kaye
Independent Director
B. Lynne Parshall
Independent Director
Sandford Smith
Independent Director
Wendall Wierenga
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CYTK
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.